These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

183 related items for PubMed ID: 9222045

  • 21. Neisseria gonorrhoeae acquires mutations in analogous regions of gyrA and parC in fluoroquinolone-resistant isolates.
    Belland RJ, Morrison SG, Ison C, Huang WM.
    Mol Microbiol; 1994 Oct; 14(2):371-80. PubMed ID: 7830580
    [Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23. Serotyping of quinolone-resistant Neisseria gonorrhoeae isolates with alterations in GyrA and ParC.
    Deguchi T, Yasuda M, Maeda SI, Saito I, Kawada Y.
    J Antimicrob Chemother; 1998 Mar; 41(3):418-20. PubMed ID: 9578173
    [No Abstract] [Full Text] [Related]

  • 24. Sequence analysis of the gyrA and parC homologues of a wild-type strain of Vibrio parahaemolyticus and its fluoroquinolone-resistant mutants.
    Okuda J, Hayakawa E, Nishibuchi M, Nishino T.
    Antimicrob Agents Chemother; 1999 May; 43(5):1156-62. PubMed ID: 10223929
    [Abstract] [Full Text] [Related]

  • 25. Topoisomerase II and IV quinolone resistance-determining regions in Stenotrophomonas maltophilia clinical isolates with different levels of quinolone susceptibility.
    Valdezate S, Vindel A, Echeita A, Baquero F, Cantó R.
    Antimicrob Agents Chemother; 2002 Mar; 46(3):665-71. PubMed ID: 11850246
    [Abstract] [Full Text] [Related]

  • 26. The effect of moxifloxacin on its target topoisomerases from Escherichia coli and Staphylococcus aureus.
    Schedletzky H, Wiedemann B, Heisig P.
    J Antimicrob Chemother; 1999 May; 43 Suppl B():31-7. PubMed ID: 10382873
    [Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29. Impact of gyrA and parC mutations on quinolone resistance, doubling time, and supercoiling degree of Escherichia coli.
    Bagel S, Hüllen V, Wiedemann B, Heisig P.
    Antimicrob Agents Chemother; 1999 Apr; 43(4):868-75. PubMed ID: 10103193
    [Abstract] [Full Text] [Related]

  • 30. Contribution of mutations in DNA gyrase and topoisomerase IV genes to ciprofloxacin resistance in Escherichia coli clinical isolates.
    Bansal S, Tandon V.
    Int J Antimicrob Agents; 2011 Mar; 37(3):253-5. PubMed ID: 21236644
    [Abstract] [Full Text] [Related]

  • 31. [Role of mutations in the A-subunit of Acholeplasma laidlawii PG-8B topoisomerase IV in formation of resistance to fluoroquinolones].
    Taganov KD, Gushchin AE, Abramycheva NIu, Govorun VM.
    Mol Gen Mikrobiol Virusol; 2000 Mar; (2):30-3. PubMed ID: 10876765
    [Abstract] [Full Text] [Related]

  • 32. Alteration in the GyrA subunit of DNA gyrase and the ParC subunit of DNA topoisomerase IV in quinolone-resistant clinical isolates of Staphylococcus epidermidis.
    Li Z, Deguchi T, Yasuda M, Kawamura T, Kanematsu E, Nishino Y, Ishihara S, Kawada Y.
    Antimicrob Agents Chemother; 1998 Dec; 42(12):3293-5. PubMed ID: 9835531
    [Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36. Occurrence of single-point gyrA mutations among ciprofloxacin-susceptible Escherichia coli isolates causing urinary tract infections in Latin America.
    Gales AC, Gordon KA, Wilke WW, Pfaller MA, Jones RN.
    Diagn Microbiol Infect Dis; 2000 Jan; 36(1):61-4. PubMed ID: 10744370
    [Abstract] [Full Text] [Related]

  • 37. Mutations in the gyrA and grlA genes of quinolone-resistant clinical isolates of methicillin-resistant Staphylococcus aureus.
    Takahata M, Yonezawa M, Kurose S, Futakuchi N, Matsubara N, Watanabe Y, Narita H.
    J Antimicrob Chemother; 1996 Sep; 38(3):543-6. PubMed ID: 8889728
    [Abstract] [Full Text] [Related]

  • 38. Molecular epidemiology of quinolone resistance in Acinetobacter spp.
    Seward RJ, Towner KJ.
    Clin Microbiol Infect; 1998 May; 4(5):248-254. PubMed ID: 11864339
    [Abstract] [Full Text] [Related]

  • 39. [Role of mutations in parC and gyrA in forming resistance of Mycoplasma hominis to fluoroquinolones].
    Gushchin AE, Ladygina VG, Govorun VM.
    Mol Gen Mikrobiol Virusol; 1999 May; (4):19-24. PubMed ID: 10621934
    [Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 10.